Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463488 | 0.89 | AVPR1A (0.38) | CHRNA7AVPR1BAVPR1A | |
| SCHEMBL2461835 | 0.89 | AVPR1B (0.53) | AVPR1BAVPR1A | |
| SCHEMBL6887357 | 0.89 | AVPR1A (0.48) | AVPR1BAVPR1A | |
| SCHEMBL6887941 | 0.89 | CYP2D6 (0.39) | CHRNA7AVPR1AMAPTMAPK1OPRL1 | |
| SCHEMBL2458959 | 0.87 | AVPR1B (0.48) | CHRNA7AVPR1BAVPR1AAKR1B10UGCG | |
| SCHEMBL2462374 | 0.82 | AVPR1B (0.42) | CHRNA7AVPR1BMAPT | |
| SCHEMBL2463199 | 0.81 | AVPR1A (0.40) | AVPR1BAVPR1A | |
| SCHEMBL6890417 | 0.81 | AVPR1B (0.51) | AVPR1BAVPR1A | |
| SCHEMBL6887462 | 0.80 | AVPR1A (0.48) | AVPR1BAVPR1A | |
| SCHEMBL6887421 | 0.79 | AVPR1B (0.54) | AVPR1BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | CHRNA7 721/4885AVPR1B 839/4885AVPR1A 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.